Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Sell
35
RGEN Quote, Financials, Valuation and Earnings
Last price:
$138.77
Seasonality move
:
3.05%
Day range:
$132.46 - $145.47
52-week range:
$102.97 - $182.52
Dividend yield:
0%
P/E ratio:
633.44x
P/S ratio:
12.36x
P/B ratio:
3.97x
Volume:
2M
Avg. volume:
920.1K
1-year change:
-16.08%
Market cap:
$7.8B
Revenue:
$634.4M
EPS (TTM):
-$0.45
Analysts' Opinion
-
Consensus RatingRepligen has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $183.40, Repligen has an estimated upside of 31.54% from its current price of $139.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $140.00 representing -0.41% downside risk from its current price of $139.43.
Fair Value
-
According to the consensus of 15 analysts, Repligen has 31.54% upside to fair value with a price target of $183.40 per share.
RGEN vs. S&P 500
-
Over the past 5 trading days, Repligen has underperformed the S&P 500 by -1.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Repligen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Repligen has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Repligen reported revenues of $167.5M.
Earnings Growth
-
Repligen earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Repligen reported earnings per share of -$0.60.
Enterprise value:
7.6B
EV / Invested capital:
--
Price / LTM sales:
12.36x
EV / EBIT:
295.22x
EV / Revenue:
11.98x
PEG ratio (5yr expected):
--
EV / Free cash flow:
53.35x
Price / Operating cash flow:
55.05x
Enterprise value / EBITDA:
94.71x
Gross Profit (TTM):
$274.6M
Return On Assets:
-0.9%
Net Income Margin (TTM):
-4.02%
Return On Equity:
-1.29%
Return On Invested Capital:
-1%
Operating Margin:
-19.88%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $801.5M | $632.4M | $634.4M | $166.6M | $167.5M | |
| Gross Profit | $455.7M | $278.4M | $274.6M | $78.5M | $38.8M | |
| Operating Income | $195.9M | $17.1M | -$31.9M | $10.6M | -$33.3M | |
| EBITDA | $277.3M | $145.3M | $80.3M | $38M | $2.1M | |
| Diluted EPS | $3.25 | $0.46 | -$0.45 | -$0.46 | -$0.60 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $902.4M | $931.7M | $998.1M | $1.1B | $1.1B | |
| Total Assets | $1.9B | $2.4B | $2.5B | $2.8B | $2.8B | |
| Current Liabilities | $319M | $375.3M | $404.2M | $164.9M | $126.8M | |
| Total Liabilities | $373.7M | $608.3M | $620.9M | $866.3M | $856.9M | |
| Total Equity | $1.5B | $1.8B | $1.9B | $2B | $2B | |
| Total Debt | $243.7M | $255.3M | $284.6M | $579.6M | $525.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $172.1M | $113.9M | $175.4M | $29.1M | $39.2M | |
| Cash From Investing | -$233.2M | -$123.3M | -$86.4M | -$169.9M | -$64.8M | |
| Cash From Financing | -$13.3M | $249M | -$82.9M | $268.1M | $1.4M | |
| Free Cash Flow | $38.7M | $74.9M | $142.5M | $17.9M | $29.2M | |
RGEN
Sector
Market Cap
$7.8B
$34.9M
Price % of 52-Week High
76.39%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-16.08%
-38.5%
Beta (5-Year)
1.266
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$139.38
200-day SMA
Sell
Level
$145.62
Bollinger Bands (100)
Sell
Level
134.7 - 161.48
Chaikin Money Flow
Buy
Level
85M
20-day SMA
Buy
Level
$129.04
Relative Strength Index (RSI14)
Buy
Level
53.45
ADX Line
Buy
Level
21.03
Williams %R
Neutral
Level
-21.6727
50-day SMA
Sell
Level
$140.94
MACD (12, 26)
Buy
Level
1.18
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
113.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.4697)
Buy
CA Score
(Annual)
Level (0.5102)
Buy
Beneish M-Score
(Annual)
Level (-2.7411)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.7682)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Stock Forecast FAQ
In the current month, RGEN has received 10 Buy ratings 5 Hold ratings, and 0 Sell ratings. The RGEN average analyst price target in the past 3 months is $183.40.
-
Where Will Repligen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Repligen share price will rise to $183.40 per share over the next 12 months.
-
What Do Analysts Say About Repligen?
Analysts are divided on their view about Repligen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Repligen is a Sell and believe this share price will drop from its current level to $140.00.
-
What Is Repligen's Price Target?
The price target for Repligen over the next 1-year time period is forecast to be $183.40 according to 15 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is RGEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Repligen is a Buy. 10 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RGEN?
You can purchase shares of Repligen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Repligen shares.
-
What Is The Repligen Share Price Today?
Repligen was last trading at $138.77 per share. This represents the most recent stock quote for Repligen. Yesterday, Repligen closed at $139.43 per share.
-
How To Buy Repligen Stock Online?
In order to purchase Repligen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 6.79% over the past day.
Sell
35
RGC alert for Apr 30
Regencell Bioscience Holdings [RGC] is up 4.3% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 1.38% over the past day.
